Drug Trial Radar · NCT00004061
Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer
Last checked: Nov 20, 2026Latest source record: Jun 26, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
111
Planned (sponsor's estimate)
Start
May 1999
Primary completion
May 2003
Study completion Dec 2009
Sponsor
- Lead sponsor
- Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- May 25, 2004
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Primary purpose
- Supportive care
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Biological therapy using growth factors may be effective in reducing side effects in patients who have hematologic cancer and are receiving radiation therapy, chemotherapy, and peripheral stem cell transplantation. PURPOSE: Randomized phase II trial to study the effectiveness of biological therapy to reduce side effects in patients who are undergoing radiation therapy, chemotherapy, and peripheral stem cell transplantation in treating lymphoma or leukemia.
Conditions
- Leukemia
- Lymphoma
- Oral Complications
Interventions
filgrastimBiological
paliferminBiological
cyclophosphamideDrug
etoposideDrug
ifosfamideDrug
peripheral blood stem cell transplantationProcedure
quality-of-life assessmentProcedure
radiation therapyRadiation
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Memorial Sloan-Kettering Cancer Center
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.